stars 1 stars 2 stars 3

Entopath's overall objective is to commercialize living insect larvae as "bioreactors" for the production of recombinant protein. Insects offer a superior pathway for producing the complex recombinant proteins often required for biopharmaceuticals. The key competitive element to the living larvae technology is the insects produce proteins faster, better, and for much less money than do other recombinant systems. The Larval Express® allows researchers to learn, first hand, the advantages of the in vivo insect system and to produce recombinant protein(s) at research scales. The kit provides the customer rapid confirmation of the protein encoded by the genetic constructs and can provide sufficient protein product for many experiments. Entopath also offers small-scale larval infection services for customers not wanting to use kits in their laboratories. Such small scale expression should be conducted prior to large-scale production.

Entopath Inc Questions

The Entopath Inc annual revenue was $3.6 million in 2026.

Entopath Inc is based in Easton, Pennsylvania.

The NAICS codes for Entopath Inc are [3254, 32, 325, 541, 54].

The SIC codes for Entopath Inc are [737, 28, 283, 73].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users